Cargando…

Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift

Tumor heterogeneity may arise through genetic drift and environmentally driven clonal selection for metabolic fitness. This would promote subpopulations derived from single cancer cells that exhibit distinct phenotypes while conserving vital pro-survival pathways. We aimed to identify significant dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Speirs, Monique M.P., Swensen, Adam C., Chan, Tsz Y., Jones, Peter M., Holman, John C., Harris, McCall B., Maschek, John A., Cox, James E., Carson, Richard H., Hill, Jonathon T., Andersen, Joshua L., Prince, John T., Price, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355186/
https://www.ncbi.nlm.nih.gov/pubmed/30728898
http://dx.doi.org/10.18632/oncotarget.26533
_version_ 1783391311693348864
author Speirs, Monique M.P.
Swensen, Adam C.
Chan, Tsz Y.
Jones, Peter M.
Holman, John C.
Harris, McCall B.
Maschek, John A.
Cox, James E.
Carson, Richard H.
Hill, Jonathon T.
Andersen, Joshua L.
Prince, John T.
Price, John C.
author_facet Speirs, Monique M.P.
Swensen, Adam C.
Chan, Tsz Y.
Jones, Peter M.
Holman, John C.
Harris, McCall B.
Maschek, John A.
Cox, James E.
Carson, Richard H.
Hill, Jonathon T.
Andersen, Joshua L.
Prince, John T.
Price, John C.
author_sort Speirs, Monique M.P.
collection PubMed
description Tumor heterogeneity may arise through genetic drift and environmentally driven clonal selection for metabolic fitness. This would promote subpopulations derived from single cancer cells that exhibit distinct phenotypes while conserving vital pro-survival pathways. We aimed to identify significant drivers of cell fitness in pancreatic adenocarcinoma (PDAC) creating subclones in different nutrient formulations to encourage differential metabolic reprogramming. The genetic and phenotypic expression profiles of each subclone were analyzed relative to a healthy control cell line (hTert-HPNE). The subclones exhibited distinct variations in protein expression and lipid metabolism. Relative to hTert-HPNE, PSN-1 subclones uniformly maintained modified sphingolipid signaling and specifically retained elevated sphingosine-1-phosphate (S1P) relative to C16 ceramide (C16 Cer) ratios. Each clone utilized a different perturbation to this pathway, but maintained this modified signaling to preserve cancerous phenotypes, such as rapid proliferation and defense against mitochondria-mediated apoptosis. Although the subclones were unique in their sensitivity, inhibition of S1P synthesis significantly reduced the ratio of S1P/C16 Cer, slowed cell proliferation, and enhanced sensitivity to apoptotic signals. This reliance on S1P signaling identifies this pathway as a promising drug-sensitizing target that may be used to eliminate cancerous cells consistently across uniquely reprogrammed PDAC clones.
format Online
Article
Text
id pubmed-6355186
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-63551862019-02-06 Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift Speirs, Monique M.P. Swensen, Adam C. Chan, Tsz Y. Jones, Peter M. Holman, John C. Harris, McCall B. Maschek, John A. Cox, James E. Carson, Richard H. Hill, Jonathon T. Andersen, Joshua L. Prince, John T. Price, John C. Oncotarget Research Paper Tumor heterogeneity may arise through genetic drift and environmentally driven clonal selection for metabolic fitness. This would promote subpopulations derived from single cancer cells that exhibit distinct phenotypes while conserving vital pro-survival pathways. We aimed to identify significant drivers of cell fitness in pancreatic adenocarcinoma (PDAC) creating subclones in different nutrient formulations to encourage differential metabolic reprogramming. The genetic and phenotypic expression profiles of each subclone were analyzed relative to a healthy control cell line (hTert-HPNE). The subclones exhibited distinct variations in protein expression and lipid metabolism. Relative to hTert-HPNE, PSN-1 subclones uniformly maintained modified sphingolipid signaling and specifically retained elevated sphingosine-1-phosphate (S1P) relative to C16 ceramide (C16 Cer) ratios. Each clone utilized a different perturbation to this pathway, but maintained this modified signaling to preserve cancerous phenotypes, such as rapid proliferation and defense against mitochondria-mediated apoptosis. Although the subclones were unique in their sensitivity, inhibition of S1P synthesis significantly reduced the ratio of S1P/C16 Cer, slowed cell proliferation, and enhanced sensitivity to apoptotic signals. This reliance on S1P signaling identifies this pathway as a promising drug-sensitizing target that may be used to eliminate cancerous cells consistently across uniquely reprogrammed PDAC clones. Impact Journals LLC 2019-01-11 /pmc/articles/PMC6355186/ /pubmed/30728898 http://dx.doi.org/10.18632/oncotarget.26533 Text en Copyright: © 2019 Speirs et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Speirs, Monique M.P.
Swensen, Adam C.
Chan, Tsz Y.
Jones, Peter M.
Holman, John C.
Harris, McCall B.
Maschek, John A.
Cox, James E.
Carson, Richard H.
Hill, Jonathon T.
Andersen, Joshua L.
Prince, John T.
Price, John C.
Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift
title Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift
title_full Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift
title_fullStr Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift
title_full_unstemmed Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift
title_short Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift
title_sort imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355186/
https://www.ncbi.nlm.nih.gov/pubmed/30728898
http://dx.doi.org/10.18632/oncotarget.26533
work_keys_str_mv AT speirsmoniquemp imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT swensenadamc imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT chantszy imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT jonespeterm imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT holmanjohnc imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT harrismccallb imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT maschekjohna imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT coxjamese imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT carsonrichardh imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT hilljonathont imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT andersenjoshual imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT princejohnt imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift
AT pricejohnc imbalancedsphingolipidsignalingismaintainedasacoreproponentofacancerousphenotypeinspiteofmetabolicpressureandepigeneticdrift